<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968587</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A0122-37</org_study_id>
    <nct_id>NCT04968587</nct_id>
  </id_info>
  <brief_title>Comparison of a RCA Ans a RACD in Extra-renal Purification by SLED</brief_title>
  <acronym>ARDC-SLED</acronym>
  <official_title>Comparison of Regional Citrate Anticoagulation and Regional Anticoagulation by Citrate-Free Decalcification in Renal Replacement Therapy Using Sustained Low-Efficiency Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Sud Ile-de-France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Sud Ile-de-France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the main RRT issue is anticoagulation of the ECC, because blood contact with&#xD;
      biomaterials causes bio-incompatibility reactions, including activation of coagulation&#xD;
      cascade. Based on Regional Citrate Anticoagulation (RCA) protocoles, an ionized calcium&#xD;
      (Caion) concentration around 0.25 to 0.35mmol / L prevents fibrinoformation and allows&#xD;
      anticoagulation for the ECC. During RCA, metabolic side effects may occur due to systemic&#xD;
      passage of citrate. Our postulate is that reduction of ionized calcemia related to the use of&#xD;
      a calcium-free dialysate and haemofilter performance makes it possible to avoid citrate&#xD;
      infusion. Our study aim to compare intermittent RRT using 4% Citrate infusion and without&#xD;
      Citrate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Renal Replacement Therapy (RRT), requires anticoagulation of the extracorporeal&#xD;
      circuit (ECC) using heparin, citrate or repeated rinsing. Difficulties of implementation or&#xD;
      exposition to complications (thrombosis, hemorrhage or electrolyte disorder) are frequent.&#xD;
&#xD;
      Purpose: Regional anticoagulation of the ECC based on ionized calcemia reduction, as using&#xD;
      citrate, but induced by the use of a calcium-free dialysate associated with the performance&#xD;
      of the hemofilter could reduce these risks and the cost of intermittent RRT. This study aims&#xD;
      to compare the efficiency of a regional anticoagulation technique based on the reduction of&#xD;
      Ionized Calcium in the extracorporeal circuit, without the use of Citrate and with Citrate&#xD;
      during intermittent RRT.&#xD;
&#xD;
      Abstract: One of the main RRT issue is anticoagulation of the ECC, because blood contact with&#xD;
      biomaterials causes bio-incompatibility reactions, including activation of coagulation&#xD;
      cascade. Based on Regional Citrate Anticoagulation (RCA) protocoles, an ionized calcium&#xD;
      (Caion) concentration around 0.25 to 0.35mmol / L prevents fibrinoformation and allows&#xD;
      anticoagulation for the ECC. During RCA, metabolic side effects may occur due to systemic&#xD;
      passage of citrate. Our postulate is that reduction of ionized calcemia related to the use of&#xD;
      a calcium-free dialysate and haemofilter performance makes it possible to avoid citrate&#xD;
      infusion. Our study aim to compare intermittent RRT using 4% Citrate infusion and without&#xD;
      Citrate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the plasma urea</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>We will compare plasma urea clearance after reaching the prescribed session time without irreversible coagulation of the extracorporeal circuit, with both methods tested in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the concentration of Ca²+i in post-filter</measure>
    <time_frame>30 minutes, 1 hour; 4 hours and 8 hours</time_frame>
    <description>Measurement at different timepoints after the beginning of the concentration of Ca²+i in post-filter during each RRT session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the concentration of Ca²+i (patient)</measure>
    <time_frame>30minutes, 1 hour; 4 hours and 8 hours</time_frame>
    <description>Measurement at different timepoints after the beginning of the concentration of Ca²+i (patient) during each RRT session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the concentration of Mg2+</measure>
    <time_frame>8 hours</time_frame>
    <description>Measurement of the concentration of Mg2+ at the end of each RRT session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of heart rate during each RRT session.</measure>
    <time_frame>Hour 0; 30 minutes; 60 minutes; 90 minutes; 120 minutes; 150 minutes; 180 minutes; 210 minutes; 240 minutes; 270 minutes; 300 minutes; 330 minutes; 360 minutes; 390 minutes; 420 minutes; 450 minutes; 480 minutes</time_frame>
    <description>Measurement heart rate during each RRT session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of blood pressure</measure>
    <time_frame>Hour 0; 30 minutes; 60 minutes; 90 minutes; 120 minutes; 150 minutes; 180 minutes; 210 minutes; 240 minutes; 270 minutes; 300 minutes; 330 minutes; 360 minutes; 390 minutes; 420 minutes; 450 minutes; 480 minutes</time_frame>
    <description>Measurement of blood pressure during each RRT session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of circuit losses during each RRT session,</measure>
    <time_frame>Hour 0; 480 minutes</time_frame>
    <description>Number of circuit losses during each RRT sessions,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of catheter thrombosis during each RRT session</measure>
    <time_frame>Hour 0; 480 minutes</time_frame>
    <description>Number of catheter thrombosis during each RRT session</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Group 1: RACD - RCA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED and second period of treatment with Regional Citrate Anticoagulation SLED</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : RCA - RACD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First period of treatment with Regional Citrate Anticoagulation SLED and second period of treatment with Regional Anticoagulation by Citrate-Free Decalcification SLED</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sustained Low-Efficiency Dialysis</intervention_name>
    <description>All patient requiring Renal replacement Therapy in the intensive care unit will be randomized in open order (cross-over) with either Regional Antigoagulation with Citrate or Regional Anticoagulation by Decalcification without Citrate</description>
    <arm_group_label>Group 1: RACD - RCA</arm_group_label>
    <arm_group_label>Group 2 : RCA - RACD</arm_group_label>
    <other_name>intermittent haemodialysis equipment with lower blood flow and dialysate flow combined with prolonged sessions</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patient requiring Renal replacement Therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Hypercalcemia ≥ 3 mmol/L.&#xD;
&#xD;
          -  Major under guardianship&#xD;
&#xD;
          -  Major deprived of liberty&#xD;
&#xD;
          -  Impossible to obtain free and informed consent&#xD;
&#xD;
          -  Presence of hemostasis or coagulation disorders:&#xD;
&#xD;
          -  Thrombocytopenia &lt; 30 G/L.&#xD;
&#xD;
          -  Curative anticoagulation.&#xD;
&#xD;
          -  Severe liver disease with PT&lt;30%.&#xD;
&#xD;
          -  Coagulation factor deficit.&#xD;
&#xD;
          -  Non-membership in a social security system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Pourcine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Sud Ile-de-France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Randazzo</last_name>
    <phone>+33181742774</phone>
    <email>caroline.randazzo@ghsif.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud Ile-de-France</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck Pourcine, MD</last_name>
      <phone>+33181742085</phone>
      <email>franck.pourcine@ghsif.fr</email>
    </contact>
    <investigator>
      <last_name>Franck Pourcine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

